RepliCel Presenting at InvestMNT Investor Conference in Minneapolis

Conference attracts investment professionals in the Twin Cities area

VANCOUVER, BC – August 3, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that RepliCel’s CEO, David Hall, will be presenting at the InvestMNT conference held in Minneapolis, Minnesota on August 5th at 8:15 AM local time. Hall’s presentation will highlight RepliCel’s 18-month milestones including CE Mark for its RCI-02 dermal injector for sale in Europe, clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials in Canada and Germany, as well as Shiseido’s proposed pattern baldness clinical trial in Japan using RepliCel’s RCH-01 (hair) product. The conference is hosted by the CFA Society of Minnesota and will take place at the Schulze School of Entrepreneurship, University of St. Thomas, Minneapolis Campus, 1000 LaSalle Avenue, Minneapolis. To learn more about the conference or if you’re interested in attending, click here.

About InvestMNT
This year’s InvestMNT conference will feature approximately 60 companies hosted by the CFA Society Minnesota, a professional organization for investment professionals located in the Twin Cities and throughout the Upper Midwest region consisting of approximately 1,300 members in five states, across a broad scope of firms.

About RepliCel
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function. The company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness. All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles. The company has also developed a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. Visit for additional information.

For more information please contact:

Tammey George, Director of Communications
Telephone: 604-248-8696 /

Lee Buckler, VP Business & Corporate Development
Telephone: 604-248-8693 /

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.